Catelani Michael purchased $16K of ANIX

Catelani Michael (President, COO, & CFO) purchased 5,500 shares of Anixa Biosciences Inc (ANIX) at $2.84 on 2026-09-30.

Original reporting
SEC EDGAR · Catelani Michael
Published Sep 30, 2026, 2:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 2:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIX
Neutral
medium confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXNeutralLow
01

Why it matters

The filing provides a fresh data point on insider sentiment but its small size limits market impact.

02

Market read

New insider purchase adds a modest positive signal for ANIX; unlikely to drive significant price movement.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: after-hours filing

Background

Form 4 filing from SEC EDGAR reporting an insider purchase by a top executive of Anixa Biosciences Inc.

Company-level read

Ticker impact

$ANIXNeutralMedium confidence
Context

President/COO/CFO bought 5,500 shares at $2.84, increasing his stake to 50,000 shares.

Expected impact

likely slight upward pressure as market notes insider confidence

Evidence & confidence

Purchase amount (~$16K) is minor relative to market cap; investors may view it as a positive signal but unlikely to move price materially.

Market effects

None significant; insider activity is company‑specific.

No broader regional effect.

Limited to investors tracking ANIX.

Counterpoint

The purchase could be a routine portfolio adjustment rather than a strong endorsement.

Key entities

  • Anixa Biosciences Inc

    Biotech firm listed on NASDAQ under ticker ANIX.

  • Catelani Michael

    President, COO, & CFO of ANIX who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIXMedAI 8/10

Anixa ovarian cancer trial to be presented at ESMO congress

Anixa Biosciences (NASDAQ:ANIX) will present Phase 1 trial results for its ovarian cancer treatment at the ESMO congress. The trial, led by Dr. Robert Wenham, evaluates the safety and efficacy of liraltagene autoleucel, a CAR-T therapy. The company reported no dose-limiting toxicities, stable disease in one patient, and over one-year survival in four patients. Anixa plans to advance to a sixth cohort with a 1,000-fold dose increase.

$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

$ANIXLowAI 8/10

Anixa completes fifth cohort dosing in ovarian cancer trial

Anixa Biosciences (NASDAQ:ANIX) completed dosing the fifth cohort in its Phase 1 trial for ovarian cancer, with no dose-limiting toxicities observed. The fifth cohort received the highest dose yet, and one patient showed stable disease 90 days post-treatment. The sixth cohort will evaluate an even higher dose. The trial, conducted at Moffitt Cancer Center, aims to assess safety, tolerability, and preliminary efficacy.

$ANIXMedAI 8/10

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.